Bolt Biotherapeutics reported clinical updates and financial results, highlighting BDC-4182's upcoming trial and completed enrollment for BDC-3042. Bolt Biotherapeutics has announced significant ...

Almost every GM EV now has access to 17,800 Tesla Superchargers for fast charging. That means the Chevy Bolt—with its modest 55-kW maximum charging rate—can now tap into Tesla’s network of 250-kW ...

Bolt Metals (TSE:BOLT) has released an update. Bolt Metals Corp. has announced a stock split where each existing common share will be split into two new shares, effectively doubling the number of ...

REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, ...

Earlier this morning, some of the first details of the new 2027 Chevrolet Bolt percolated out onto the internet thanks to some people that attended a special preview for existing owners last night in ...

General Motors recently announced that GM EV customers now have access to the Tesla Supercharger network, opening up over 17,800 chargers and expanding available charging solutions to more than ...

Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers Presented updated preclinical activity of BDC-4182 and key learnings from ...

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), ...

First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 ...

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund ...